BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SYH2070 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SYH2070\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07695597-1097@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:SYH2070: Phase 2 readout est. (NCT07695597)
DESCRIPTION:SYH2070\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemi
 a\nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/syh2070#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07695597
URL:https://assetmemo.bio/drug/syh2070#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591298-1097@assetmemo.bio
DTSTAMP:20261121T005704Z
DTSTART;VALUE=DATE:20270916
DTEND;VALUE=DATE:20270917
SUMMARY:SYH2070: Phase 2 readout est. (NCT07591298)
DESCRIPTION:SYH2070\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH207
 0 Injection in Participants With Homozygous Familial Hypercholesterolemia\
 nEstimated primary completion: 16 September 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/syh2070#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07591298
URL:https://assetmemo.bio/drug/syh2070#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
